Display options
Cite
Shohrati M, Bayat N, Saburi A, et al. Effect of Nasal Calcitonin on the Health-Related Quality of Life in Postmenopause Women Affected With Low Bone Density. Iran Red Crescent Med J. 2015;17(7):e6613doi: 10.5812/ircmj.17(5)2015.6613.
Shohrati, M., Bayat, N., Saburi, A., & Abbasi, Z. (2015). Effect of Nasal Calcitonin on the Health-Related Quality of Life in Postmenopause Women Affected With Low Bone Density. Iranian Red Crescent medical journal, 17(7), e6613. https://doi.org/10.5812/ircmj.17(5)2015.6613
Shohrati, Majid, et al. "Effect of Nasal Calcitonin on the Health-Related Quality of Life in Postmenopause Women Affected With Low Bone Density." Iranian Red Crescent medical journal vol. 17,7 (2015): e6613. doi: https://doi.org/10.5812/ircmj.17(5)2015.6613
Shohrati M, Bayat N, Saburi A, Abbasi Z. Effect of Nasal Calcitonin on the Health-Related Quality of Life in Postmenopause Women Affected With Low Bone Density. Iran Red Crescent Med J. 2015 Jul 31;17(7):e6613. doi: 10.5812/ircmj.17(5)2015.6613. eCollection 2015 Jul. PMID: 26421180; PMCID: PMC4584075.
Copy Download .nbib Format: NLM
Share it on

Iran Red Crescent Med J. 2015 Jul 31;17(7):e6613. doi: 10.5812/ircmj.17(5)2015.6613. eCollection 2015 Jul.

Effect of Nasal Calcitonin on the Health-Related Quality of Life in Postmenopause Women Affected With Low Bone Density.

Iranian Red Crescent medical journal

Majid Shohrati, Noushin Bayat, Amin Saburi, Zahra Abbasi

Affiliations

  1. Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
  2. Internal Diseases Department, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
  3. Radiology Department, Birjand Atherosclerosis and Coronary Artery Research Center, Birjand University of Medical Sciences, Birjand, IR Iran.
  4. Pharmaceutical Sciences Branch, Islamic Azad University (IAUPS), Tehran, IR Iran.

PMID: 26421180 PMCID: PMC4584075 DOI: 10.5812/ircmj.17(5)2015.6613

Abstract

BACKGROUND: Physical activity and mental health could be affected by osteoporosis and various therapeutic options such as calcitonin may influence Quality Of Life (QOL) of these patients with Low Bone Density (LBD).

OBJECTIVES: This study aimed to evaluate the effect of nasal calcitonin on QOL in post menopause women with LBD.

PATIENTS AND METHODS: This clinical trial study was performed on one hundred and fifteen menopause women with LBD less than 1 SD in Bone Mineral Densitometry (BMD) referred to Baqiyatallah Hospital in Tehran, Iran, during 2009 - 2010. They were assigned to receive 200 IU calcitonin nasal spray along with calcium (1000 mg) and vitamin D (400 IU) for 6 months. Quality of life was assessed by Short-Form 36 (SF-36) questionnaire (Persian-validated version).

RESULTS: The mean age (± SD) of the participants was 58.75 ± 8.15 years. Intranasal spray of calcitonin increased QOL scores significantly (88.05 ± 15.63 vs. 92.15 ± 13.22, P value = 0.000). Bone mineral density of spine was increased from 0.834 ± 0.11 to 0.12 ± 0.852 and this difference in BMD of lumbar spine was statistically significant (P value: 0.003) but not significant in femur's BMD (P value = 0.061). In comparison with BMD indexes, The QOL scores especially Mental Health domain changes had only a significant correlation with the changes of total T score in BMD (P = 0.031, Coefficient Correlation = 0.248).

CONCLUSIONS: It seems that nasal spray of calcitonin can effectively improve QOL of women with LBD and QOL changes were not influenced by clinical or para-clinical alteration. Mental health domain must be more considered in further studies as a predicting domain for Health-Related Quality of Life (HR-QOL) changes.

Keywords: Bone Density; Osteoporosis; Oteoporosis; Postmenopausal; Quality of Life, Calcitonin

References

  1. Calcif Tissue Int. 1996 Jul;59(1):6-11 - PubMed
  2. Clin J Pain. 1999 Dec;15(4):284-9 - PubMed
  3. J Bone Miner Metab. 2007;25(3):184-92 - PubMed
  4. Osteoporos Int. 2008 Jan;19(1):21-8 - PubMed
  5. Am J Med. 2000 Sep;109 (4):267-76 - PubMed
  6. J Clin Epidemiol. 1998 Nov;51(11):1105-13 - PubMed
  7. Osteoporos Int. 2010 Nov;21(11):1817-24 - PubMed
  8. J Bone Miner Res. 2002 Mar;17 (3):521-7 - PubMed
  9. Rheumatol Int. 2006 Feb;26(4):288-91 - PubMed
  10. Calcif Tissue Int. 2002 Dec;71(6):478-84 - PubMed
  11. Best Pract Res Clin Rheumatol. 2010 Dec;24(6):793-810 - PubMed
  12. Soc Sci Med. 1995 Nov;41(10):1349-58 - PubMed
  13. Clin Rheumatol. 2005 Jun;24(3):232-8 - PubMed
  14. JAMA. 2009 Feb 4;301(5):513-21 - PubMed
  15. Qual Life Res. 2005 Apr;14(3):875-82 - PubMed
  16. Osteoporos Int. 2000;11(8):688-96 - PubMed
  17. Osteoporos Int. 1999;10(4):259-64 - PubMed
  18. J Sci Med Sport. 2012 Mar;15(2):102-9 - PubMed
  19. Osteoporos Int. 2004 Oct;15(10):834-41 - PubMed
  20. CMAJ. 2002 Nov 12;167(10 Suppl):S1-34 - PubMed
  21. Osteoporos Int. 2004 Dec;15(12):975-80 - PubMed
  22. Clin Rheumatol. 2007 Jan;26(1):44-9 - PubMed
  23. Osteoporos Int. 2000;11 Suppl 6:S66-76 - PubMed
  24. East Mediterr Health J. 2005 May;11(3):349-57 - PubMed
  25. Calcif Tissue Int. 1991;49 Suppl 2:S9-13 - PubMed
  26. J Clin Epidemiol. 1998 Nov;51(11):1095-103 - PubMed
  27. Curr Pharm Des. 2003;9(32):2659-76 - PubMed

Publication Types